TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03033914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg q14 days
Study: NCT02207530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 monotherapy
Study: NCT02590016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Aspart
Description: Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Aspart
Description: Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
Study: NCT02971644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cobalt alloy pedicle screw implantation
Description: The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
Study: NCT04388735

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
Study: NCT03556722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation.
Description: High frequency rTMS on left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
Study: NCT05537324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazil nut
Description: Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts

Intervention type: OTHER
Group type: OTHER
Intervention: Coconut
Description: Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
Study: NCT03105154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevena Dressing
Description: Prevena dressing is applied on one groin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing
Description: Conventional dressing is applied on the contralateral groin
Study: NCT01576861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin
Description: Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
Study: NCT02829086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relationship Enhancement
Description: Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relationship Enhancement
Description: Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Stress and Conflict Management
Description: Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Management
Description: Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
Study: NCT00192335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIV-T

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIVT
Description: The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Study: NCT05427851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
Study: NCT01611506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle
Study: NCT04640194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
Study: NCT03033914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg q14 days
Study: NCT03059030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Description: The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
Study: NCT05427851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser - fonalaser
Description: diode laser beam application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser - fonalaser
Description: diode laser beam application
Study: NCT03313505

Intervention type: BIOLOGICAL
Intervention: S100B protein dosage
Description: S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient

Intervention type: OTHER
Intervention: Brain CT scan
Description: No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
Study: NCT04640194

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
Study: NCT02267512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-F
Description: Intravenous (IV)
Study: NCT04125134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free Refresh Optive Advanced Lubricant Eye Drops
Description: over the counter artificial tear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free Refresh Optive Advanced Lubricant Eye Drops
Description: over the counter artificial tear
Study: NCT01777815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord DS1000 Artificial Chordae Delivery System
Study: NCT00540358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: Gemcitabine and carboplatin administered according to instructions in the package inserts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin
Description: Gemcitabine and carboplatin administered according to instructions in the package inserts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iniparib
Description: Body weight adjusted dose~1 hour intravenous infusion
Study: NCT02364869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide
Description: Patients will be evaluated at baseline, week 6 and 12.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
Study: NCT04618172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minute long exercises twice a week
Study: NCT01663896

Intervention type: DEVICE
Intervention: OCT stent guidance
Description: Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
Study: NCT03036592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
Study: NCT02604680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-1
Description: BLI1100-1 Topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-2
Description: BLI1100-2 Topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-3
Description: BLI1100-3 Topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-4
Description: BLI1100-4 Topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Topical gel
Study: NCT00385736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
Study: NCT00385736

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
Study: NCT03306238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open approach to port insertion
Description: This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed approach to port insertion
Description: This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
Study: NCT00048139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 250mg/m2 iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-15 of each 3 week cycle
Study: NCT03595722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: High intensity focused ultrasound to rectal/pelvic cancer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: High intensity focused ultrasound to rectal/pelvic cancer
Study: NCT03621215

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Description: 30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fruit-flavoured placebo drink
Description: Consumed daily by participants, with breakfast, for 12 months.
Study: NCT03377998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
Study: NCT03189927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD-Covered esophageal stent
Description: a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
Study: NCT02477033

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyricicoccus pullicaecorum 25-3T

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT02144818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovitrel
Description: Triggering of ovulation with Ovitrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovitrel
Description: Triggering of ovulation with Ovitrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: Triggering with GnRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl
Description: Triggering with GnRH agonist
Study: NCT00908141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously on varying schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously on varying schedule
Study: NCT01188590

Intervention type: DEVICE
Intervention: TOSCA 500 monitor
Description: transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
Study: NCT02349854

Intervention type: PROCEDURE
Intervention: Biopsy
Description: 1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.

Intervention type: PROCEDURE
Intervention: Biopsy
Description: 1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
Study: NCT03344120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of USSQ Symptoms questionnaire after stent positioning
Description: Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of USSQ Symptoms questionnaire after stent positioning
Description: Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
Study: NCT01894009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foot manipulation
Description: The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham foot manipulation
Description: Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
Study: NCT03119896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Navigator Tool Intervention
Description: The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
Study: NCT04111952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: A single session of CO2 vaginal laser treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: A single session of sham laser treatment.